全文获取类型
收费全文 | 6810篇 |
免费 | 369篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 67篇 |
儿科学 | 70篇 |
妇产科学 | 70篇 |
基础医学 | 746篇 |
口腔科学 | 215篇 |
临床医学 | 405篇 |
内科学 | 1866篇 |
皮肤病学 | 74篇 |
神经病学 | 507篇 |
特种医学 | 413篇 |
外科学 | 1415篇 |
综合类 | 32篇 |
预防医学 | 172篇 |
眼科学 | 181篇 |
药学 | 337篇 |
中国医学 | 5篇 |
肿瘤学 | 649篇 |
出版年
2023年 | 41篇 |
2022年 | 35篇 |
2021年 | 146篇 |
2020年 | 84篇 |
2019年 | 123篇 |
2018年 | 155篇 |
2017年 | 119篇 |
2016年 | 113篇 |
2015年 | 148篇 |
2014年 | 171篇 |
2013年 | 223篇 |
2012年 | 400篇 |
2011年 | 396篇 |
2010年 | 236篇 |
2009年 | 226篇 |
2008年 | 363篇 |
2007年 | 349篇 |
2006年 | 339篇 |
2005年 | 384篇 |
2004年 | 319篇 |
2003年 | 335篇 |
2002年 | 315篇 |
2001年 | 164篇 |
2000年 | 163篇 |
1999年 | 182篇 |
1998年 | 70篇 |
1997年 | 39篇 |
1996年 | 57篇 |
1995年 | 50篇 |
1994年 | 50篇 |
1993年 | 49篇 |
1992年 | 119篇 |
1991年 | 121篇 |
1990年 | 122篇 |
1989年 | 111篇 |
1988年 | 107篇 |
1987年 | 121篇 |
1986年 | 101篇 |
1985年 | 106篇 |
1984年 | 47篇 |
1983年 | 45篇 |
1982年 | 27篇 |
1981年 | 24篇 |
1979年 | 46篇 |
1978年 | 26篇 |
1977年 | 41篇 |
1974年 | 24篇 |
1971年 | 19篇 |
1970年 | 19篇 |
1969年 | 20篇 |
排序方式: 共有7224条查询结果,搜索用时 78 毫秒
1.
Yusuke Satoh Hitoshi Kotani Yuichi Iida Takahito Taniura Yoshitomo Notsu Mamoru Harada 《Cancer science》2020,111(7):2248-2258
Myeloid‐derived suppressor cells (MDSCs) play a crucial role in immunosuppression in tumor‐bearing hosts. MDSCs express arginase‐I and indoleamine 2,3‐dioxygenase; they suppress T‐cell function by reducing the levels of l ‐arginine and l ‐tryptophan, respectively. We examined the anticancer effects of supplementation of these amino acids in CT26 colon carcinoma‐bearing mice. Oral supplementation of l ‐arginine or l ‐tryptophan (30 mg/mouse) did not affect tumor growth, whereas oral supplementation of d ‐arginine was lethal. Supplementation of l ‐arginine showed a tendency to augment the efficacy of cyclophosphamide (CP). CP reduced the proportions of granulocytic MDSCs and increased the proportions of monocytic MDSCs in the spleen and tumor tissues of CT26‐bearing mice. l ‐Arginine supplementation alone did not affect the MDSC subsets. CP treatment tended to reduce the plasma levels of l ‐arginine in CT26‐bearing mice and significantly increased the number of tumor‐infiltrating CD8+ T cells. In addition, l ‐arginine supplementation significantly increased the proportions of tumor peptide‐specific CD8+ T cells in draining lymph nodes. Importantly, additional supplementation of l ‐arginine significantly increased the number of cured mice that were treated with CP and anti‐PD‐1 antibody. Totally, l ‐arginine supplementation shows promise for boosting the therapeutic efficacy of chemoimmunotherapy. 相似文献
2.
Norihiko Matsutani Hiroto Furuta Shohei Matsuno Yoshimasa Oku Shuhei Morita Shinsuke Uraki Asako Doi Machi Furuta Hiroshi Iwakura Hiroyuki Ariyasu Masahiro Nishi Takashi Akamizu 《Journal of diabetes investigation.》2020,11(2):333-336
Activating mutations in the ABCC8 gene cause diabetes and inactivating mutations usually cause hyperinsulinemic hypoglycemia in infancy. Patients with hypoglycemia in infancy due to a heterozygous inactivating mutation have been reported to occasionally progress to diabetes later in life. We explored the gene responsible for diabetes in two brothers, who were suspected to have diabetes at 15 and 18 years‐of‐age, respectively, with whole exome sequencing, and identified a compound heterozygous ABCC8 gene mutation (p.Arg168Cys and p.Arg1421Cys). Although their father and mother were heterozygous carriers of the p.Arg168Cys and the p.Arg1421Cys mutation, respectively, neither parent had diabetes. These mutations have been reported to be responsible for hypoglycemia in infancy and function as an inactivating mutation. Our results suggest that the inactivating ABCC8 gene mutation is also important in the etiology of diabetes. 相似文献
3.
4.
5.
Mihoko Hatano Yoshihiro Matsumoto Jun-ichi Fukushi Tomoya Matsunobu Makoto Endo Seiji Okada Kunio Iura Satoshi Kamura Toshifumi Fujiwara Keiichiro Iida Yuko Fujiwara Akira Nabeshima Nobuhiko Yokoyama Suguru Fukushima Yoshinao Oda Yukihide Iwamoto 《Clinical & experimental metastasis》2015,32(6):579-591
6.
Kiyotaka Nemoto Tetsuya Shimokawa Masaki Fukunaga Fumio Yamashita Masashi Tamura Hidenaga Yamamori Yuka Yasuda Hirotsugu Azechi Noriko Kudo Yoshiyuki Watanabe Mikio Kido Tsutomu Takahashi Shinsuke Koike Naohiro Okada Yoji Hirano Toshiaki Onitsuka Hidenori Yamasue Michio Suzuki Kiyoto Kasai Ryota Hashimoto Tetsuaki Arai 《Psychiatry and clinical neurosciences》2020,74(1):56-63
7.
8.
Naohiro Sekiguchi Shinya Rai Wataru Munakata Kenshi Suzuki Hiroshi Handa Hirohiko Shibayama Tomoyuki Endo Yasuhito Terui Noriko Iwaki Noriko Fukuhara Hiro Tatetsu Shinsuke Iida Takayuki Ishikawa Ryota Shiibashi Koji Izutsu 《Cancer science》2020,111(9):3327-3337
Tirabrutinib is a second‐generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment‐naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström’s macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression‐free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88L265P mutation. MRR and ORR were 88.9% and 96.3%, respectively (Cohort A: MRR, 88.9%; ORR, 94.4%; Cohort B: MRR, 88.9%; ORR, 100%). Median TTMR was 1.87 mo. PFS and OS were not reached with a median follow‐up of 6.5 and 8.3 mo for Cohorts A and B, respectively. The most common adverse events (AEs) were rash (44.4%), neutropenia (25.9%), and leukopenia (22.2%), with most AEs classified as grade 1 or 2. Grade ≥ 3 AEs included neutropenia (11.1%), lymphopenia (11.1%), and leukopenia (7.4%). No grade 5 AEs were noted. All bleeding events were grade 1; none were associated with drug‐related atrial fibrillation or hypertension. Although the follow‐up duration was relatively short, the study met the primary endpoint. Therefore, tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile. (JapicCTI‐173646). 相似文献
9.
10.
Tomohiro Saito Masahide Mizobuchi Yusuke Miwa Motonori Sugiyama Yuuki Mima Ayana Iida Nobuhiro Kanazawa Tomoki Morikawa Junichi Hayashi Kei Fukuda Yasuto Shikida Taihei Suzuki Hirokazu Honda 《Journal of clinical apheresis》2021,36(1):196-205
We present six cases of antimelanoma differentiation‐associated gene 5 antibody (anti‐MDA5‐Ab)‐positive clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP‐ILD), which is known to have a poor prognosis. The outcomes of these cases are described after treatment with therapeutic plasma exchange (TPE). Clinical and therapeutic data for patients with CADM with RP‐ILD were collected retrospectively from medical records. All six patients received early intensive care including high‐dose corticosteroids, intravenous cyclophosphamide, and a calcineurin inhibitor, but lung disease and hypoxia became more severe. TPE was performed over a median of 9.5 sessions (range 3‐14) per patient, and the median duration from admission to TPE was 23 days. Three patients received combined direct hemoperfusion using a polymyxin B‐immobilized fiber column (PMX‐DHP) therapy on successive days to manage acute respiratory failure. Four patients survived and two died due to respiratory failure. In the survival cases, ferritin decreased, and ferritin and KL‐6 were lower at diagnosis. The patients who died had a higher alveolar‐arterial oxygen difference and more severe lung lesions at the time of initiation of TPE. These findings indicate that a combination of conventional therapy and TPE may be useful for improvement of the prognosis of CADM with RP‐ILD at the early stage of onset. 相似文献